Something positive today from Piper Jaffray from an hour or so ago
Insmed call pushed out awaiting Arikayce data, says Piper Jaffray
Piper Jaffray said Insmed did not host a conference call in conjunction with its Q4 earnings report, but plans to hold a call when top-line Phase 2 data for Arikayce to treat nontuberculous mycobacteria infections are released in late March. Piper said it has confidence in the data and long term prospects for Arikayce in NTM and reiterates its Overweight rating and $45 price target on Insmed.
Today was a buying opportunity. Did you buy more shares people? Nice to have liquidity when these kind of days roll by. I added shares today, good luck, INSM is 92% institutionally owned, they were buying today, not selling. Retail sells and insty's buy.